Quest Diagnostics EVP sells 632 company shares

Quest Diagnostics executive Catherine T. Doherty reported sales and related share dispositions of company stock.

Rhea-AI Filing Summary

Quest Diagnostics executive Catherine T. Doherty reported sales and related share dispositions of company stock. On March 3, 2026, she executed an open-market sale of 632 shares of common stock at $207.73 per share, leaving 67,122 shares held directly.

On March 2, 2026, 648 shares were disposed of at $204.86 per share to cover tax obligations tied to the vesting of restricted share units, and the sale activity was carried out under a pre-arranged Rule 10b5-1 trading plan. She also holds 4,502 shares indirectly through a company 401(k)/profit sharing plan.

Insider Trade Summary

Net Seller: 632 shares

Net Sell 3 txns

Insider Doherty Catherine T.

Role EVP, Regional Businesses

Sold 632 shs ($131K)

Type	Security	Shares	Price	Value
Sale	Common Stock	632	$207.73	$131K
Exercise Price or Tax Liability	Common Stock	648	$204.86	$133K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 67,122 shares (Direct); Common Stock — 4,502 shares (Indirect, 401(k)/SDCP)

Footnotes (3)

1. F1. Sale of common stock to satisfy tax obligations arising from the vesting of a previous grant of restricted share units.
2. F2. This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
3. F3. These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under the Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider stock transactions did Quest Diagnostics (DGX) EVP Catherine Doherty report?

Catherine Doherty reported selling 632 Quest Diagnostics common shares at $207.73 each and disposing of 648 shares at $204.86 to cover tax obligations from restricted share unit vesting, while maintaining over 67,000 shares of direct ownership plus additional shares in a company retirement plan.

Were Catherine Doherty’s Quest Diagnostics (DGX) stock sales part of a 10b5-1 trading plan?

Yes. The filing notes that at least one reported Quest Diagnostics stock sale was executed under a Rule 10b5-1 trading plan. These pre-arranged plans allow insiders to schedule trades in advance, providing a structured framework for transactions while the insider may later possess material nonpublic information.

How many Quest Diagnostics (DGX) shares does Catherine Doherty own after the reported transactions?

After the reported trades, Catherine Doherty directly owns 67,122 Quest Diagnostics common shares. She also has an indirect interest in 4,502 additional shares through the company’s tax-qualified 401(k)/profit sharing plan, held in a company stock fund managed by a plan trustee.

What was the purpose of the 648-share Quest Diagnostics (DGX) disposition reported by Catherine Doherty?

The 648-share disposition was used to satisfy tax obligations arising from the vesting of a previous grant of restricted share units. Instead of paying cash, shares were delivered to cover withholding, which is a common method for handling equity-related tax liabilities for executives.

At what prices did Catherine Doherty’s recent Quest Diagnostics (DGX) transactions occur?

Her open-market sale of 632 Quest Diagnostics shares occurred at $207.73 per share. The separate 648-share disposition related to tax withholding was priced at $204.86 per share, reflecting the stock’s value when those shares were used to satisfy the equity award tax obligations.

How are Catherine Doherty’s indirect Quest Diagnostics (DGX) holdings structured?

Her indirect holdings of 4,502 Quest Diagnostics shares are in the company’s tax-qualified Profit Sharing (401(k)) Plan. A trustee acquires underlying shares periodically, and her portion is calculated by dividing her stock fund account balance by Quest Diagnostics’ market price as of a current date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 04:39 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Doherty Catherine T.

(Last) (First) (Middle)

500 PLAZA DRIVE

(Street)

SECAUCUS NJ 07094

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Regional Businesses

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		F		648(1)	D	$204.86	67,754	D
Common Stock	03/03/2026		S(2)		632	D	$207.73	67,122	D
Common Stock								4,502(3)	I	401(k)/SDCP

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sale of common stock to satisfy tax obligations arising from the vesting of a previous grant of restricted share units.

2. This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

3. These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under the Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date.

Remarks:

	Sean D. Mersten, Attorney in Fact for Catherine T. Doherty	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.